Vaccine Partnership Conference 2017 logo

Hear from exciting new vaccine biotechs presenting on their pipeline as well as case studies and on how best to form public-private partnerships



This conference provides a space for those directly involved in cementing the details of partnerships with big pharma, biotechs, academia and non-profit organisations to share their case studies and gain insight into best practice.

If you are looking for potential partnerships and collaborations, makes sure you participate in this conference to meet new vaccine biotechs showcasing their technology and pipeline.




Partnerships April 12, Wednesday 12 April 2017

Dr Leonard Friedland
Partnerships April 12

Developing new standards for building trust with pharmaceutical companies: A reflection on GlaxoSmithKline’s (GSK’s) journey

  • Changing the standard ways of working that industry uses with its academic and public health customers
  • How to become a trusted partner in the scientific and public health community to deliver the best quality of healthcare to patients
  • Changing the standard ways of working that industry uses with its academic and public health customers
  • How to become a trusted partner in the scientific and public health community to deliver the best quality of healthcare to patients
Dr Annie De Groot
Partnerships April 12

Ancer™: An immunoinformatic platform for personalized cancer vaccine delivery

Dr Michael Vajdy
Partnerships April 12

Demonstrating the safety and efficacy profile of an alternative adjuvant delivery system against influenza


Networking coffee break


Networking Lunch & Poster Session

Dr Luis H. Martin
Partnerships April 12

UBER Vaccinology:  A new operational and funding paradigm for vaccine innovation

  • Publically funded, not-for-profit model to de-risk vaccine development to meet public health needs and industry thresholds
  • Effective leveraging of funding through networks and partnerships
  • Fostering partnerships to drive vaccine innovation
  • Attaining self-sustainability in a not-for-profit organization
Dr Alan R. Hinman

The eradication of Polio: Have we succeeded?

-    Measuring and monitoring the success of eradication
-    End game and strategic plan
-    What’s next? Can we eradicate measles?
Dr Roman Chicz
Partnerships April 12

Areas of interest for big pharma: External collaborative research and partnering opportunities for vaccine development

Session led by: sanofi-pasteur-inc
Professor Robert Daum

A call for greater consideration for the role of vaccines in national strategies to combat antibiotic-resistant bacteria

-    Recommendations from the National Vaccine Advisory Committee
-    Use of vaccines to prevent the infections that could or have developed AMR to antibiotics, in adjunction to antibiotic stewardship
-    Examples in Haemophilus influenza, Streptococcus, Staphylococcus aureus

Dr Rodolfo Alarcon
Partnerships April 12

Support mechanisms to develop vaccines with better effectiveness: Why does the effectiveness of the rotavirus vaccine drop in middle to low income countries?

  • What vaccines are the NIH prioritizing and why?
  • How could we increase the efficacy of existing vaccines and why does it drop in low to middle income countries?
  • How to access government funding for vaccine development programs
Dr Rodolfo Alarcon, Program Officer, NIH
Panel discussion

Panel: How much efficacy is enough? What are the implications of a vaccine no longer being a replacement technology but a companion technology?

-    The concept of partially protected vaccines like malaria, TB, NTDs where the clinical efficacy is no longer 85/90% but closer to 40% 
-    Future of vaccine development 
-    The combining drivers of technology and emerging diseases

More panelists to be announced shortly
Dr Ole Olesen
Partnerships April 12

Addressing the fragmented landscape of funding opportunities for companies and academic developers of vaccines

  • How can different funders and vaccine developers work together to improve the environment of vaccine development
  • Setting global priorities for vaccine development

Chair’s closing remarks and close of congress

last published: 28/Mar/17 16:43



Sign up for event updates


  • Pharma
  • Biotech
  • National and International Government
  • Non-Profit Organizations
  • Academics and Research Institutions
  • Consultants
  • Venture capitalists
  • Investors
  • Lawyers ​


  • CEO / CSO / COO
  • Head of Corporate Development
  • Head of Licensing/Out-Licensing
  • Head of Pipeline Management
  • Head of Outsourcing
  • Head of Strategy
  • Head of Alliancing/alliance management
  • Head of Legal/Contracts
  • Partner strategy and implementation lead
  • External R&D​




This is a key opportunity for specialists in vaccines from:​

  • Platform Technology Providers
  • Biotechs
  • Big Pharma
  • Consultants with expertise in vaccine development and execution
  • Consultants on Legal affairs
  • Consultants on Regulatory Affairs ​